LightDeck Diagnostics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.0m | Series A | |
N/A | $3.9m | Early VC | |
N/A | $6.3m | Series B | |
* | $220k | Grant | |
N/A | $620k | Debt | |
$5.2m | Series B | ||
$1.6m | Debt | ||
$630k | Grant | ||
$6.1m | Debt | ||
$11.0m | Series B | ||
* | N/A | Grant | |
* | $38.7m Valuation: $38.7m | Acquisition | |
Total Funding | CAD39.9m |
Recent News about LightDeck Diagnostics
EditLightDeck Diagnostics operates in the medical diagnostics market, providing advanced testing solutions through its innovative planar waveguide technology. The company serves healthcare providers, laboratories, and industries requiring rapid and accurate diagnostic results. LightDeck's core product is a portable analyzer that uses inexpensive, disposable test cartridges to deliver lab-quality results in minutes. This technology is particularly valuable in situations requiring quick decision-making, such as emergency rooms or remote locations. The business model revolves around the sale of these analyzers and recurring revenue from the disposable cartridges. LightDeck Diagnostics generates revenue through direct sales and partnerships with healthcare institutions and governmental bodies. The company has received several awards and certifications, including ISO 13485, which affirms its commitment to quality management. Recent funding rounds, such as the $11 million Series B, support the development of new tests, including a 5-minute COVID-19 test.
Keywords: diagnostics, planar waveguide, portable analyzer, disposable cartridges, lab-quality, rapid testing, healthcare, emergency rooms, remote locations, ISO 13485.